ResearcherUniversidad de GranadaNo recent work listed
Gloria Perazzoli
Matched on ORCID iD 0000-0003-2205-749X; OpenAlex author ID A5076607721. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers
Papers 6
- Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. Co-author DOI 10.2147/ijn.s415631↗
- Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review. Co-author DOI 10.3390/metabo13070872↗
- PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine. Co-author DOI 10.1016/j.biopha.2022.113669↗
- The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study. Co-author DOI 10.3390/cancers13133169↗
- Nanomedicine in Pancreatic Cancer: A New Hope for Treatment. First author DOI 10.2174/1389450121666200703195229↗
- The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Co-author DOI 10.20892/j.issn.2095-3941.2019.0252↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Consolación Melguizo Alonso · 6 shared papers, 2019–2023 · strength 0.91
- Paper Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review. DOI 10.3390/metabo13070872↗
- Paper Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. DOI 10.2147/ijn.s415631↗
- Paper PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcit… DOI 10.1016/j.biopha.2022.113669↗
- Jose Carlos Prados · 6 shared papers, 2019–2023 · strength 0.91
- Paper Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review. DOI 10.3390/metabo13070872↗
- Paper Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. DOI 10.2147/ijn.s415631↗
- Paper PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcit… DOI 10.1016/j.biopha.2022.113669↗
- Francisco Quiñonero · 5 shared papers, 2019–2023 · strength 0.69
- Paper Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. DOI 10.2147/ijn.s415631↗
- Paper PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcit… DOI 10.1016/j.biopha.2022.113669↗
- Paper The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro a… DOI 10.3390/cancers13133169↗
- Cristina Jiménez‐Luna · 4 shared papers, 2019–2023 · strength 0.66
- Paper Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review. DOI 10.3390/metabo13070872↗
- Paper Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. DOI 10.2147/ijn.s415631↗
- Paper PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcit… DOI 10.1016/j.biopha.2022.113669↗
- Raúl Ortíz · 3 shared papers, 2021–2023 · strength 0.48
- Paper Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. DOI 10.2147/ijn.s415631↗
- Paper PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcit… DOI 10.1016/j.biopha.2022.113669↗
- Paper The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro a… DOI 10.3390/cancers13133169↗
- Kevin Doello González · 3 shared papers, 2019–2021 · strength 0.35
- Paper The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro a… DOI 10.3390/cancers13133169↗
- Paper Nanomedicine in Pancreatic Cancer: A New Hope for Treatment. DOI 10.2174/1389450121666200703195229↗
- Paper The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. DOI 10.20892/j.issn.2095-3941.2019.0252↗
- Pablo Redruello Guerrero · 1 shared paper, 2020 · strength 0.11
- Antonio Jesús Láinez Ramos‐Bossini · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.